-
公开(公告)号：US5334710A
公开(公告)日：1994-08-02
申请号：US50941
申请日：1993-04-21
申请人： Markus Ahlheim , Friedrich Lehr
发明人： Markus Ahlheim , Friedrich Lehr
IPC分类号： C07C219/08 , C07C233/16 , C07C245/08 , C07C253/30 , C07C255/58 , C07C255/65 , C07D333/60 , C07D333/64 , C08F20/34 , C08F20/38 , C08F36/04 , C08F36/20 , C09B23/00 , C09B23/01 , C09B29/08 , C09B29/085 , G02F1/361
CPC分类号： C07D333/64 , C07C245/08 , C07C255/65 , C07D333/60 , C08F20/34 , C09B23/0091 , C09B29/0813 , G02F1/3611 , G02F1/3614 , G02F1/3617
摘要： The invention relates to monomeric or polymeric organic compounds having non-linear optical properties, to their production and to their use as electrooptical, photorefractive or holographic devices, especially as modulators, switches, amplifiers, wave guides, sensors to work as sequence transformation especially frequency doubling. These compounds are compounds of Formula I: ##STR1## in which R.sub.1 is a group for formula a ##STR2## or R.sub.1 is a group of formula b ##STR3## or R.sub.1 is an NO.sub.2 where R.sub.1`-R.sub.11 are organic radicals.
摘要翻译： 本发明涉及具有非线性光学性质的单体或聚合物有机化合物，其生产及其作为电光，光折射或全息装置的用途，特别是作为调制器，开关，放大器，波导，用作序列变换的传感器，特别是频率 翻倍 这些化合物是式I的化合物：其中R 1是式a的基团（a）或R 1是式b的基团（b）或R 1是NO 2，其中R 1 '-R11是有机基团。
-
公开(公告)号：US20140363513A1
公开(公告)日：2014-12-11
申请号：US14467212
申请日：2014-08-25
申请人： Markus Ahlheim , Holger Petersen
发明人： Markus Ahlheim , Holger Petersen
CPC分类号： A61K9/0019 , A61K9/14 , A61K9/1647 , A61K9/1694 , A61K38/12 , A61K38/31 , A61K47/10 , A61K47/26 , A61K47/34 , A61K47/38 , A61M5/19 , A61M5/24
摘要： The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two different linear polylactide-co-glycolide polymers (PLGAs).
摘要翻译： 本发明涉及包含奥曲肽或其药学上可接受的盐和两种不同的线性聚丙交酯 - 共 - 乙交酯聚合物（PLGAs）作为活性成分的持续释放制剂。
-
公开(公告)号：US20130012542A1
公开(公告)日：2013-01-10
申请号：US13618753
申请日：2012-09-14
IPC分类号： C07D413/04 , A61P25/18 , A61K31/454
CPC分类号： A61K31/454 , A61K9/0019 , A61K47/10 , A61K47/26 , A61K47/38
摘要： An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
-
公开(公告)号：US20110212141A1
公开(公告)日：2011-09-01
申请号：US13106417
申请日：2011-05-12
IPC分类号： A61K9/14 , A61K31/454 , A61P25/18
CPC分类号： A61K31/454 , A61K9/0019 , A61K47/10 , A61K47/26 , A61K47/38
摘要： An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
摘要翻译： 包含具有结构（I）的晶体的可注射贮库制剂，其中R为（FII）且晶体的X 50值为1至200微米。 含有伊立替康或其代谢物晶体的储备制剂具有以下优点：（i）等离子体中晶体的释放可与晶体尺寸相关; （ii）等离子体中的晶体的吸收可以与晶体的大小相关; （iii）可以通过晶体工程和/或研磨来控制晶体的粒度; 和（iv）晶体在储存时是稳定的，并且对灭菌过程如γ辐射是稳定的。
-
5.发明申请SUSTAINED RELEASE FORMULATION COMPRISING OCTREOTIDE AND THREE LINEAR POLYLACTIDE-CO-GLYCOLIDE POLYMERS 审中-公开包含OCTREOTIDE和三种线性聚乙二醇 - 聚甘油聚合物的持续释放配方公开(公告)号：US20110003002A1
公开(公告)日：2011-01-06
申请号：US12865145
申请日：2009-01-29
申请人： Holger Petersen , Markus Ahlheim
发明人： Holger Petersen , Markus Ahlheim
CPC分类号： A61K9/1694 , A61K9/0019 , A61K9/0024 , A61K9/06 , A61K9/10 , A61K9/1647 , A61K38/31
摘要： The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and three different linear polylactide-co-glycolide polymers (PLGAs).
摘要翻译： 本发明涉及包含作为活性成分奥曲肽或其药学上可接受的盐和三种不同的线性聚丙交酯 - 共 - 乙交酯聚合物（PLGAs）的缓释制剂。
-
6.发明申请公开(公告)号：US20060189683A1
公开(公告)日：2006-08-24
申请号：US10548737
申请日：2004-03-31
申请人： Markus Ahlheim
发明人： Markus Ahlheim
IPC分类号： A61K31/365
CPC分类号： A61K47/02 , A61K9/0019 , A61K31/343 , A61K47/26
摘要： A pharmaceutical composition in the form of powder or a lyophilized composition for injection suitable for parenteral administration comprising MPA, a salt or a produg thereof.
摘要翻译： 粉末形式的药物组合物或适用于肠胃外给药的注射用冻干组合物，其包含MPA，其盐或其产物。
-
7.发明申请Sustained Release Formulation Comprising Octreotide and Two or More Polyactide-co-glycolide Polymers 审中-公开包含奥曲肽和两种或多种聚酰胺 - 共 - 乙交酯聚合物的缓释制剂公开(公告)号：US20150037420A1
公开(公告)日：2015-02-05
申请号：US14516016
申请日：2014-10-16
申请人： Holger Petersen , Markus Ahlheim
发明人： Holger Petersen , Markus Ahlheim
CPC分类号： A61K38/12 , A61K9/0019 , A61K9/10 , A61K9/14 , A61K9/1647 , A61K9/50 , A61K9/5015 , A61K9/5089 , A61K38/08 , A61K38/31 , A61K47/32 , A61K47/34
摘要： The present invention relates to sustained release formulations comprising as active ingredient octreotide or a pharmaceutically-acceptable salt thereof and two or more different polylactide-co-glycolide polymers (PLGAs).
摘要翻译： 本发明涉及包含作为活性成分奥曲肽或其药学上可接受的盐和两种或更多种不同的聚丙交酯 - 共 - 乙交酯聚合物（PLGAs）的缓释制剂。
-
公开(公告)号：US08293765B2
公开(公告)日：2012-10-23
申请号：US13106417
申请日：2011-05-12
IPC分类号： A01N43/00 , A01N43/40 , A61K31/553 , A61K31/554 , A61K31/445 , C08J9/28 , C07D211/22 , C07D261/20
CPC分类号： A61K31/454 , A61K9/0019 , A61K47/10 , A61K47/26 , A61K47/38
摘要： An injectable depot formulation comprising crystals having structure (I) wherein R is (FII) and the X50 value of the crystals is from 1 to 200 microns. Depot formulations containing crystals of iloperidone or its metabolites have the following advantages: (i) release of the crystals in plasma can be correlated with the size of the crystals; (ii) absorption of the crystals in plasma can be correlated with the size of the crystals; (iii) the particle size of the crystals can be controlled by crystal engineering and/or milling; and (iv) the crystals are stable upon storage, and stable to sterilization procedures, such as gamma irradiation.
摘要翻译： 包含具有结构（I）的晶体的可注射贮库制剂，其中R为（FII）且晶体的X 50值为1至200微米。 含有伊立替康或其代谢物晶体的储备制剂具有以下优点：（i）等离子体中晶体的释放可与晶体尺寸相关; （ii）等离子体中的晶体的吸收可以与晶体的大小相关; （iii）可以通过晶体工程和/或研磨来控制晶体的粒度; 和（iv）晶体在储存时是稳定的，并且对灭菌过程如γ辐射是稳定的。
-
公开(公告)号：US20120214749A1
公开(公告)日：2012-08-23
申请号：US13456681
申请日：2012-04-26
CPC分类号： A61K38/31 , A61K9/1647 , Y10S977/788
摘要： Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.
摘要翻译： 公开了包含嵌入用于长效释放的生物相容性药理学可接受的聚合物基质中的生长抑素类似物的微粒和包含这种微粒的药物组合物。
-
公开(公告)号：US07759308B2
公开(公告)日：2010-07-20
申请号：US10579186
申请日：2004-11-12
IPC分类号： A61K38/12
CPC分类号： A61K38/31 , A61K9/1647 , Y10S977/788
摘要： Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.
摘要翻译： 公开了包含嵌入用于长效释放的生物相容性药理学可接受的聚合物基质中的生长抑素类似物的微粒和包含这种微粒的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
28 条记录 (耗时 0.016 秒)
